Abstract:An animal model of gram-positive septicemia was developed to evaluate the effects of antithrombin (AT) concentrates on morbidity, mortality, and laboratory consequences of disseminated intravascular coagulation (DIC). DIC was induced in guinea pigs by infusing Staphylococcus aureus (SA) isolated from blood cultures of patients with DIC (DIC-SA) or without DIC (non-DIC-SA). The non-DIC-SA animals and animals infused with sterile saline served as controls. Varying doses of AT were administered either 30 minutes or 24 hours after infusion of SA. DIC was confirmed within 4 hours by changes in prothrombin time, activated partial thromboplastin time, fibrinogen, fibrinogen-fibrin degradation products, and AT activity. Clinical bleeding was also evident. Mortality of untreated DIC-SA animals was 36% within 24 hours and up to 75% by 72 hours. Intervention with any dose of AT between 125 and 1,000 IU/kg 30 minutes after DIC-SA infusion was associated with 100% survival (P < or = .05 in the 250 IU/kg group) and sustained increases in AT activity and fibrinogen concentrations (P < or = .05). When AT was administered in combination with low molecular weight heparin (LMWH) or if LMWH was adminstered alone, mortality from DIC-SA was slightly, but not significantly reduced compared with untreated DIC-SA. Gross hemorrhage was observed premortem and at autopsy in all of the DIC-SA animals but in substantially fewer animals that received AT (P < or = .001 in the 250, 500, and 1,000 IU/kg groups). In contrast, groups treated with LMWH, alone or with AT, experienced hemorrhage and appeared to develop pathologic DIC. Fibrin formation in end-organs was detected in all guinea pigs in the untreated DIC-SA group and in the groups treated with 125 IU/kg AT and LMWH alone. AT doses between 250 and 1,000 IU/kg administered 30 minutes after DIC-SA infusion prevented fibrin formation in end-organs (P < or = .001 in the 250 and 1,000 IU/kg groups). AT administered 24 hours after DIC-SA could not reverse pre-existing histopathologic evidence of DIC but favorably affected survival, which reached statistical significance in the 1,000 IU/kg AT group (P < or = .025). In summary, suprapharmacologic doses of AT concentrate significantly decreased morbidity and mortality and ameliorated adverse changes in laboratory measures induced by DIC-SA in this guinea pig model and were not associated with untoward hemorrhagic complications. These findings provide justification for studying the use of AT therapy in patients with DIC-SA.

Novel Recombinant Fibrinogenase of Agkistrodon Acutus Venom Protects Against LPS-induced DIC.

A Novel Fibrinogenase from Agkistrodon Acutus Venom Protects Against DIC Via Direct Degradation of Thrombosis and Activation of Protein C.

The effect of fibrinolytic enzyme FIIa from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits.

Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-α

A Novel Fibrinogenase from Agkistrodon Acutus Venom Protects Against LPS-induced Endotoxemia Via Regulating NF-κB Pathway.

A Novel Recombinant Fibrinogenase of Agkistrodon Acutus Venom Protects Against Hyperacute Rejection Via Degradation of Complements

A Novel Recombinant Snake Venom Metalloproteinase From Agkistrodon Acutus Protects Against Taurocholate-Induced Severe Acute Pancreatitis In Rats

The Effect of the Fibrinolytic Enzyme FIIa from Agkistrodon Acutus Venom on Acute Pulmonary Thromboembolism

A recombinant fragment of von Willebrand factor reduces fibrin-rich microthrombi formation in mice with endotoxemia

Andrographolide Had Positive Effects On Anti-Inflammatory And Protected Against Lps-Induced Dic In Rabbits

[Effects of Urokinase Intervention on Endotoxin-Induced DIC in Wistar Rat Model].

Polyunsaturated fatty acid-derived lipid mediator Resolvin D1 alleviates sepsis-induced disseminated intravascular coagulation via Caspase-1/Gasdermin D pyroptotic pathway

The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity

Atractylenolide Ⅰ Protects Against Lipopolysaccharide-Induced Disseminated Intravascular Coagulation by Anti-Inflammatory and Anticoagulation Effect.

Corrigendum to “A Novel Fibrinogenase from Agkistrodon Acutus Venom Protects Against DIC Via Direct Degradation of Thrombosis and Activation of Protein C” [biochem. Pharmacol. 84 (2012) 905–913]

Effect of Xueshuantong Injection on LPS-induced DIC in Rabbits

Antagonism by salvianolic acid B of lipopolysaccharide-induced disseminated intravascular coagulation in rabbits.

A Factor XIa Inhibitor Engineered from Banded Krait Venom Toxin: Efficacy and Safety in Rodent Models of Arterial and Venous Thrombosis

Salvianolic acid A alleviates lipopolysaccharide-induced disseminated intravascular coagulation by inhibiting complement activation

Enzymological Characterization of FIIa, a Fibrinolytic Enzyme from Agkistrodon Acutus Venom

Attempt for a Recombinant Thrombomodulin Alpha Treatment in a Rat Disseminated Intravascular Coagulation Model Using Yamakagashi (Rhabdophis tigrinus) Venom